Genentech CFO Lou Lavigne to retire
Thursday, 11 November, 2004
Genentech has announced that its chief financial officer, Lou Lavigne, will retire next March and will be replaced by David Ebersman, currently senior vice president of product operations.
Ebersman joined Genentech in 1994 and was named senior director of product development in 1998, vice president of product development in 1999 and senior vice president of product operations in 2001.
He became a member of Genentech's executive committee in March 2004.
Before joining Genentech, Ebersman was a research analyst covering biotechnology at Oppenheimer & Company, which is now CIBC World Markets. Ebersman will be replaced by Pat Yang, currently vice president of South San Francisco Manufacturing and Engineering.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
